Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Jiguang Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6242-6248; OpenAlex author ID A5020194440. Sources: OpenAlex.

Their work

Papers
41 (first author 8, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2013: 3 papers · 2014: 5 papers · 2015: 6 papers · 2016: 3 papers · 2017: 3 papers · 2018: 7 papers · 2019: 6 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 41

  1. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Last author DOI 10.1016/j.canlet.2025.217497↗
  2. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Co-author DOI 10.1016/j.biopha.2022.112713↗
  3. Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence. Last author DOI 10.1155/2022/9658890↗
  4. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  5. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Last author DOI 10.1016/j.biopha.2020.110116↗
  6. Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor. Last author DOI 10.1136/rapm-2019-100991↗
  7. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  8. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.01038↗
  9. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  10. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  11. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway. Co-author DOI 10.1177/0963689719851772↗
  12. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  13. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  14. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  15. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. First author DOI 10.1002/jcb.27266↗
  16. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Last author DOI 10.1016/j.csbj.2018.10.006↗
  17. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  18. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Co-author DOI 10.1159/000494547↗
  19. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Last author DOI 10.1186/s13046-018-0740-4↗
  20. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Last author DOI 10.3892/ijo.2018.4573↗
  21. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. Co-author DOI 10.3892/or.2018.6518↗
  22. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  23. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  24. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  25. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  26. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. First author DOI 10.18632/oncotarget.7776↗
  27. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Last author DOI 10.3390/nu8100546↗
  28. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. First author DOI 10.1080/15384047.2015.1040952↗
  29. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  30. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  31. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  32. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  33. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.5045↗
  34. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Co-author DOI 10.1016/j.canlet.2014.02.003↗
  35. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. First author DOI 10.1155/2014/546353↗
  36. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-3426↗
  37. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signa… First author DOI 10.1186/1471-2407-14-686↗
  38. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. First author DOI 10.2174/1568009614666140402105101↗
  39. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. First author DOI 10.1186/1476-4598-12-66↗
  40. Indometacin ameliorates high glucose-induced proliferation and invasion via modulation of e-cadherin in pancreatic cancer cells. Co-author DOI 10.2174/09298673113209990249↗
  41. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. First author DOI 10.2174/09298673113209990251↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 40 shared papers, 2013–2025 · strength 2.94
  2. Wanxing Duan · 33 shared papers, 2013–2025 · strength 2.20
  3. Weikun Qian · 18 shared papers, 2017–2025 · strength 1.81
  4. Zheng Wang · 19 shared papers, 2014–2022 · strength 1.31
  5. Erxi Wu · 22 shared papers, 2013–2022 · strength 1.24
  6. Qinhong Xu · 23 shared papers, 2013–2020 · strength 1.24
  7. Xuqi Li · 21 shared papers, 2013–2020 · strength 1.18
  8. Ying Xiao · 11 shared papers, 2018–2022 · strength 1.15
  9. Cancan Zhou · 14 shared papers, 2016–2021 · strength 1.07
  10. Jianjun Lei · 19 shared papers, 2013–2021 · strength 1.06
  11. Tao Qin · 9 shared papers, 2018–2022 · strength 0.97
  12. Liang Cheng · 12 shared papers, 2017–2020 · strength 0.93
  13. Zheng Wu · 13 shared papers, 2013–2022 · strength 0.87
  14. Zhengdong Jiang · 13 shared papers, 2015–2019 · strength 0.79
  15. Ke Chen · 9 shared papers, 2016–2022 · strength 0.74
  16. Liankang Sun · 10 shared papers, 2016–2020 · strength 0.72
  17. Liang Han · 10 shared papers, 2013–2025 · strength 0.71
  18. Jie Li · 7 shared papers, 2017–2021 · strength 0.60
  19. Junyu Cao · 8 shared papers, 2017–2019 · strength 0.60
  20. Liang Han · 9 shared papers, 2014–2021 · strength 0.59
  21. Tao Qin · 5 shared papers, 2018–2025 · strength 0.58
  22. Bin Yan · 7 shared papers, 2017–2019 · strength 0.52
  23. Zheng Wang · 2 shared papers, 2020–2025 · strength 0.34
  24. Zhenhua Ma · 7 shared papers, 2014–2017 · strength 0.33
  25. Xin Chen · 5 shared papers, 2015–2018 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.